Protalix BioTherapeutics (NYSE:PLX) Downgraded to Buy Rating by StockNews.com
Protalix BioTherapeutics (NYSE:PLX – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Separately, HC Wainwright upped their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on […]
Protalix BioTherapeutics (NYSE:PLX – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Separately, HC Wainwright upped their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on […]
